RxDoctor Payments Data

Yvette Canaba, DPM

Primary Podiatric Medicine · Santee, CANPI 1821426388

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (54.5%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Biotissue Holdings Inc. at 32.0% of the total. Reporting peaked in 2024 at $1,682 and has fallen 78.1% since, to $368 in 2025.

$4,999in general payments, 2019–2025

Across 78 payments — averaging $64.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$2K
  • Medical Device Business Services, Inc.$1K
  • Smith+Nephew$666
  • AbbVie$215
  • Organogenesis Inc.$168
  • Acera Surgical, Inc.$146
  • plus $1K from 19 others

What the payments were for

  • Speaking & faculty fees$1252%
  • Travel & lodging$2,15243%
  • Food & beverage$2,72254%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,999 in reported general payments places this provider in the 85th percentile of 59 primary podiatric medicine providers in California.

See all primary podiatric medicine providers in California

Medicare billing

Part B allowed, 2024
$17,642
Medicare patients
58
Services billed
179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ketoconazole56$1,179
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen31$529
Terbinafine Hcl13$198
Nystatin15$182
Cephalexin13$140
Clotrimazole12$126
Meloxicam12$90

Paid to pharmacies, not to this prescriber.

Other primary podiatric medicine in Santee

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →